13 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
27 Sep 23
Regulation FD Disclosure
6:58am
Label warnings for skin discoloration Black box warning for retinal abnormalities/vision loss FDA Drug Safety Communication: Potiga (ezogabine) [04-26
424B4
BHVN
Biohaven Ltd.
24 Oct 22
Prospectus supplement with pricing info
9:38am
by regulatory authorities of additional warnings on the label, such as a “black box” warning or contraindication;
requirement that we implement a REMS
S-1/A
BHVN
Biohaven Ltd.
20 Oct 22
IPO registration (amended)
10:00am
or the manufacturing process for any component thereof;
requirement by regulatory authorities of additional warnings on the label, such as a “black
S-1
vsunz7ia
18 Oct 22
IPO registration
4:03pm
DRS
k93s3z
11 Oct 22
Draft registration statement
12:00am
10-12B/A
EX-99.1
97fd91 gn6u6
20 Sep 22
Registration of securities (amended)
6:30am
10-12B/A
EX-99.1
ua6azggbwho
14 Sep 22
Registration of securities (amended)
5:25pm
10-12B/A
EX-99.1
d1xe4rk7aqtdj1b4gkb2
7 Sep 22
Registration of securities (amended)
7:26am
10-12B/A
EX-99.1
akvm92g
24 Aug 22
Registration of securities (amended)
5:03pm
10-12B
EX-99.1
gb9fijg2
10 Aug 22
Registration of securities
5:07pm
DRS
EX-99.1
q7lbo597dgfeqf
1 Jul 22
Draft registration statement
12:00am
- Prev
- 1
- Next